Help
RSS
API
Feed
Maltego
Contact
Domain > ir.ibioinc.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2018-02-18
34.225.153.50
(
ClassC
)
2024-06-25
184.169.177.203
(
ClassC
)
2024-07-16
52.52.110.122
(
ClassC
)
2025-01-01
54.151.77.31
(
ClassC
)
Port 443
HTTP/1.1 200 OKDate: Tue, 25 Jun 2024 19:40:32 GMTServer: ApacheX-Frame-Options: SAMEORIGINStrict-Transport-Security: max-age31536000;X-XSS-Protection: 1; modeblockX-Content-Type-Options: nosniffVary: !DOCTYPE html>html langen> head> meta charsetutf-8> meta http-equivx-ua-compatible contentieedge> base hrefhttps://ir.ibioinc.com /> link relalternate typeapplication/rss+xml titleiBio Inc. - Recent News hrefhttps://ir.ibioinc.com/news-events/press-releases/rss /> title>Investor Relations :: iBio Inc. (IBIO)/title> link relcanonical hrefhttps://ir.ibioinc.com>meta propertyog:url contenthttps://ir.ibioinc.com>meta propertyog:site_name contentiBio Inc.>meta propertyog:title contentInvestor Relations>meta propertyog:type contentwebsite>meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_e934703747a3c0cb3081609c2a2d6086/ibioinc/db/366/2791/social_image_resized.jpg>meta nametwitter:card contentsummary_large_image>meta propertyog:description contentiBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other…>meta namedescription contentiBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other…>script typeapplication/ld+json> {@context:http://schema.org,@type:Corporation,name:iBio Inc.,address:{@type:PostalAddress,streetAddress:1750 Sorrento Valley Road Suite 200,addressLocality:San Diego, CA,postalCode:92121,addressCountry:},legalName:iBio Inc.,description:iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBiou2019s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information,
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]